
Hi,
I do not think it will reached 0.52, too drastic down. I think fair value to look forward to collect is around 0.67 - 0.65. take care !
To be fair, buy only when price is 0.52 as IPO price is 0.46.
Bio-Treat Tech (BIOT) has suffered a large plunge since its high of S$1.38
in Apr 06, losing almost 51% in price.
- Elliot wave counts indicate BIOT is in its final leg of a larger corrective
wave (Wave B).
- While candlestick patterns have yet to present a reversal formation, traded
volume has been declining over the last 5 weeks, indicating the downtrend
momentum is waning.
- Price indicators have slipped into oversold regions, thus are poised for a
rebound in the near-term.
- We expect to witness price consolidation in the near-term, as BIOT
attempts to test our immediate support zone of S$0.60 - 0.65.
- Immediate resistance sits at S$0.80, breaking which, our next resistance
is set at S$1.00.
- We advocate buying into weakness for Bio-Treat Technology.
[Source: OCBC]
Hey,
It is moving up at 0.695, just now also hit 0.7 !
It said because of an accounting error there are "material differences in the revenue and cost of sales items in its unaudited year to June 2006 financial statement and those in its audited financial report for the year, and it is restating the figures.
The revenue and cost of sales items in the audited financial statement were stated as RMB1.56b and RMB1.03b respectively, higher than the RMB1.46b yuan and RMB934.3m stated in the unaudited statement, Bio-Treat said. The correct figures were those contained in the audited statement, it said.
The company said these differences arose because of a classification error. The error was discovered after the unaudited financial statements were released in August.
"The company wishes to assure shareholders that this error in classification is a one-off event," Bio-Treat said in a statement.
"The group has tightened its accounts department internal control procedures to prevent such incidents from recurring in the future," it added.
Broken below $0.695.
IFC's investment in Epure is a testimony to its capabilities and strong track record. This would help boost the companies corporate governance. In this respect, Epure is much better than Bio-treat and is a good alternative. Investors may switch from Bio-treat to Epure. Epure is also able to handle larger sized projects than Bio-treat.
Hi Allantanhc Senior,
Other than this one, any suggestion such as .... Can you please highlight. Thks.
There is good support for this counter at this price level. Not sure if people will hold when the price moves up. There is a no-confidence issue here.
Purely from technical point of view, there are other better Chinese counters.
Hi,
Now all China stocks start to move again, and this counter had down quite a lot, should it be the correct time to play in and tag along the China wave ! Can anyone comment please.